Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2025
Sparsentan for treating primary IgA nephropathy [ID6308]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2025
Dapagliflozin for treating chronic kidney disease [ID6411]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 2 July 2025
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 December 2025
Iptacopan for treating complement 3 glomerulopathy [ID6283]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 8 January 2026
Obinutuzumab with immunosuppressive therapies for treating lupus nephritis [ID6420]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 March 2026
Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sibeprenlimab for treating IgA nephropathy [TSID12111]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Atrasentan for treating primary IgA nephropathy [ID6588]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC